CFTC files to dismiss CME lawsuit over crypto perpetual futures
Reported by Cointelegraph · AI-assisted summary by ChikoCorp AI News Desk
AI-generated summary based on the linked source; not independently verified. This is not investment advice. Verify market-moving details at the original publisher before acting. See our editorial policy, AI content policy, and financial disclaimer.
Summary
The US Commodity Futures Trading Commission (CFTC) has filed a motion to dismiss a lawsuit brought by the Chicago Mercantile Exchange (CME) Group. CME’s lawsuit challenged the CFTC’s classification of cryptocurrency perpetual futures as "swaps" rather than "futures," claiming this treatment violated the Commodity Exchange Act. The CFTC argues that CME lacks standing because it has not shown any concrete financial injury from the commission’s actions.
Why it matters
The source explains the dispute centers on regulatory classification and authority over crypto perpetual futures, affecting how these products are authorized and traded. The CFTC’s dismissal effort suggests ongoing regulatory debates around crypto derivatives continue to have legal and market implications. The source does not elaborate further on broader market or policy effects.
Key context
CME filed the lawsuit in June after the CFTC approved perpetual futures contracts linked to Bitcoin spot prices for Kalshi and issued a no-action letter for similar products on Coinbase. CME contended the CFTC Chair acted unilaterally without the full commission panel, contravening the Commodity Exchange Act. The CFTC’s position is that any registered exchange can list such perpetual futures, so CME is not financially harmed.
Key numbers and entities
The main organizations involved are the US Commodity Futures Trading Commission (CFTC), its Chair Michael Selig, Chicago Mercantile Exchange (CME) Group, Kalshi prediction markets platform, and Coinbase exchange. No specific financial figures are provided.
What remains unclear
The source does not detail the timeline for the hearing requested by the CFTC or the ultimate resolution of the case. It is also unclear what specific business impacts CME alleges beyond general claims of regulatory overreach and how other market participants might be affected.